Natixis Advisors, L.P. Catalyst Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 45,637 shares of CPRX stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,637
Previous 33,146
37.68%
Holding current value
$1.03 Million
Previous $513,000
76.8%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$424 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$182 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$141 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$129 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$68.4 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.33B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...